Pazopanib

CHEMBL477772 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
437.5 g/mol
LogP
3.1
Phase
4

This targeted cancer medication treats kidney cancer and soft tissue sarcoma by blocking tumor blood vessel growth.

Masse moléculaire

437,5000 g/mol

LogP

3,10

TPSA

127,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O

InChI

InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)

Molecular Formula

C21H23N7O2S

HBD / HBA

2 / 8

Liaisons Rotatives

5

Atomes Lourds

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This targeted cancer medication treats kidney cancer and soft tissue sarcoma by blocking tumor blood vessel growth.

Yes, Pazopanib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL477772. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10113978. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.